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ABSTRACT
Objective: The current pathological diagnostic criteria
for sporadic inclusion body myositis (IBM) lack
sensitivity. Using immunohistochemical techniques
abnormal protein aggregates have been identified in
IBM, including some associated with
neurodegenerative disorders. Our objective was to
investigate the diagnostic utility of a number
of markers of protein aggregates together with
mitochondrial and inflammatory changes in IBM.
Design: Retrospective cohort study. The sensitivity of
pathological features was evaluated in cases of Griggs
definite IBM. The diagnostic potential of the most
reliable features was then assessed in clinically typical
IBM with rimmed vacuoles (n=15), clinically typical
IBM without rimmed vacuoles (n=9) and IBM mimics
—protein accumulation myopathies containing rimmed
vacuoles (n=7) and steroid-responsive inflammatory
myopathies (n=11).
Setting: Specialist muscle services at the John
Radcliffe Hospital, Oxford and the National Hospital for
Neurology and Neurosurgery, London.
Results: Individual pathological features, in isolation,
lacked sensitivity and specificity. However, the
morphology and distribution of p62 aggregates in IBM
were characteristic and in a myopathy with rimmed
vacuoles, the combination of characteristic p62
aggregates and increased sarcolemmal and internal
major histocompatibility complex class I expression
or endomysial T cells were diagnostic for IBM with a
sensitivity of 93% and specificity of 100%. In an
inflammatory myopathy lacking rimmed vacuoles, the
presence of mitochondrial changes was 100%
sensitive and 73% specific for IBM; characteristic
p62 aggregates were specific (91%), but lacked
sensitivity (44%).
Conclusions: We propose an easily applied
diagnostic algorithm for the pathological diagnosis of
IBM. Additionally our findings support the hypothesis
that many of the pathological features considered
typical of IBM develop later in the disease, explaining
their poor sensitivity at disease presentation and
emphasising the need for revised pathological criteria
to supplement the clinical criteria in the diagnosis
of IBM.
INTRODUCTION
Sporadic inclusion body myositis (IBM) is
the commonest acquired myopathy in those
aged over 50 years.1 Although classiﬁed as an
idiopathic inﬂammatory myopathy, muscle
biopsy reveals both degenerative and inﬂam-
matory features. The widely used Griggs diag-
nostic criteria require the presence of several
pathological ﬁndings,2 namely rimmed
vacuoles, an inﬂammatory inﬁltrate with inva-
sion of non-necrotic ﬁbres by mononuclear
inﬂammatory cells (partial invasion), and
either amyloid deposits or 15–18 nm tubulo-
ﬁlaments identiﬁed by electron microscopy
(EM), for a diagnosis of deﬁnite IBM.
Although these features in combination are
highly speciﬁc for IBM, individually they
occur in other myopathies, including some
important in the differential diagnosis for
IBM.3–7 Moreover, cases of clinically typical
IBM have been reported where the combin-
ation of these pathological features is absent
causing diagnostic difﬁculty.8–11
Strengths and limitations of this study
▪ The present study is a multicentre retrospective
evaluation of the diagnostic utility of pathological
findings for differentiating inclusion body myo-
sitis (IBM) from myopathies important in the dif-
ferential diagnosis—protein accumulation
myopathies containing rimmed vacuoles and
steroid-responsive inflammatory myopathies.
▪ The main strength of our study was the system-
atic detailed analysis of well-defined cases. This
enabled us to determine the sensitivity and spe-
cificity of individual pathological features and
produce an easily applied pathological diagnostic
algorithm for IBM for use in clinical practice.
▪ Study limitations include the small number of
cases and the retrospective design. Further pro-
spective studies are now required in larger
cohorts of patients.
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Over the past two decades, pathological accumulation
of many different proteins has been reported in muscle
ﬁbres in IBM.12 Proteins typically associated with
neurodegenerative diseases such as β-amyloid (Aβ),
hyperphosphorylated tau and ubiquitin and newer neu-
rodegenerative markers such as p62 and transactivation
response DNA binding protein-43 (TDP-43) have
been identiﬁed, as well as proteins associated with myoﬁ-
brillar myopathies (MFM), including desmin and
αB-crystallin. However, not all observations have been
consistently reproduced.13 14 Mitochondrial changes
have also been proposed for inclusion in IBM diagnos-
tic criteria.15 Clear guidelines for the incorporation of
immunohistochemical ﬁndings and mitochondrial
changes into diagnostic criteria for IBM have not been
established.16
Previously, we have shown that the characteristic
pattern of weakness associated with IBM is indicative of
the diagnosis, even if the Griggs pathological features
are absent.11 However, it is not invariably found at pres-
entation. Here we sought to identify which pathological
features, other than those included in the Griggs patho-
logical criteria, add further support to the diagnosis of
IBM. We systematically investigated which pathological
features are present in Griggs pathologically deﬁnite
IBM and then established the diagnostic utility of these
features in cases of IBM lacking pathological features
included in the Griggs criteria, using myopathies con-
sidered in the differential diagnosis of IBM as controls.
MATERIALS AND METHODS
Cases
All patients were followed by specialist muscle services at
the John Radcliffe Hospital, Oxford and the National
Hospital for Neurology and Neurosurgery, London.
Biopsies were taken for diagnostic purposes from the
deltoid or quadriceps muscles and prior to any
treatment.
Methods for demonstrating pathological features in
IBM, additional to those deﬁned by the Griggs criteria,
were determined in six Griggs pathologically deﬁnite
cases of IBM. Cases with no clinical or pathological evi-
dence of neuromuscular disease were used as controls.
The diagnostic utility of the pathological features identi-
ﬁed was assessed in two groups of clinically typical IBM;
one with rimmed vacuoles on muscle biopsy (IBM+RV;
n=15), the other without rimmed vacuoles on muscle
biopsy (IBM −RV; n=9). Disease controls were cases of
steroid-responsive inﬂammatory myopathies (polymyosi-
tis and dermatomyositis; (PM&DM); n=11) and protein
accumulation myopathies with rimmed vacuoles (PAM;
n=7). Clinical characteristics and inclusion criteria are
summarised in online supplementary tables S1 and S2.
Tissue from brains donated to the Queen Square Brain
Bank for Neurological Disorders was used as positive
controls for protein aggregate staining.
Muscle biopsies
Muscles biopsies were snap frozen at the time of surgery
in isopentane cooled liquid nitrogen. Until sectioning
all samples were stored at −80°C. Serial tissue sections
were cut to a thickness of 8 µm, allowed to air dry and
stored at −80°C until staining. Prior to staining, tissue
sections were allowed to dry at room temperature.
Tissue sections were stained with haematoxylin and
eosin (H&E), combined cytochrome oxidase (COX)
succinate dehydrogenase (SDH) histochemistry and for
amyloid using alkalinised Congo red, crystal violet and
thioﬂavin S. Tissue sections for immunohistochemical
staining were ﬁxed for 10 min, if required, washed for
5 min in running water and incubated in 0.5% hydrogen
peroxide to block endogenous peroxidase for 20 min.
After further washing, tissue sections were incubated in
5% normal goat serum (Vector Laboratories,
Burlingame, California, USA) for 30 min and then sys-
tematically stained for: (1) proteins classically associated
with neurodegenerative disease: tau and hyperpho-
sphorylated tau, ubiquitin, Aβ and α-synuclein; (2) pro-
teins recently reported in neurodegenerative disease:
p62, TDP-43, fused in sarcoma protein (FUS) and
valosin containing protein (VCP); (3) nuclear mem-
brane proteins: lamin A/C and emerin; (4) proteins
associated with MFM: desmin, myotilin and αB-crystallin
and (5) inﬂammatory cells and major histocompatibility
complex class I (MHC class I): CD3 T cells, CD4 T cells,
CD8 T cells, B cells and macrophages. Primary antibody
binding was visualised using Dako REAL EnVision
Detection System which contains horse-radish peroxid-
ase (HRP) labelled goat anti-rabbit/mouse secondary
and 3,3′-diaminobenzidine (DAB); following incubation
with the relevant primary antibody, tissue sections were
washed in phosphate-buffered saline (PBS), incubated
with HRP labelled goat anti-rabbit/mouse secondary for
30 min, washed in PBS and incubated in a 1:50 solution
of DAB for 3–5 min. Details of commercial antibodies
and conditions used are provided in online supplemen-
tary table S3. Immunohistochemistry (IHC) for each
antibody was performed on all cases simultaneously
including positive and negative controls (see online sup-
plementary ﬁgure S1).
Definitions and quantification
The total number of ﬁbres and the number undergoing
partial invasion, containing rimmed vacuoles, protein
aggregates and COX-negative SDH-positive (COX
−/SDH+) ﬁbres were quantiﬁed using ImagePro V.6.2
(Media Cybernetics), to ensure that the whole biopsy
was systematically analysed. Only transversely orientated
ﬁbres not undergoing necrosis or regeneration were
quantiﬁed. Tissue sections stained with Congo red were
visualised under ﬂuorescent and polarised light. Areas
of ﬂuorescence were examined using both rhodamine
red (excitation 512–546 nm and emission 600–640 nm)
and ﬂuorescein isothiocyanate (excitation 440–480 nm
and emission 527–530 nm) ﬁlters to exclude
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autoﬂuorescence. Online supplementary table S4 pro-
vides deﬁnitions of the pathological features assessed.
The inﬂammatory inﬁltrate and MHC class I staining
were analysed using a modiﬁed version of the semiquan-
titative juvenile dermatomyositis score tool (see online
supplementary ﬁgure S2).17 Assessments were per-
formed blind to clinical details and diagnosis by a single
individual (SB). Ten per cent of slides were recounted
to assess intra-observer reliability and 336 slides were
assessed independently by two observers (SB and JLH)
to determine inter-observer reliability.
Statistical analysis
Statistical analyses were performed using GraphPad
PRISM V.5. Continuous and categorical variables were
compared using Mann-Whitney U test and χ2 or Fisher’s
exact test, respectively. Spearman’s rank order correl-
ation was used to determine the strength and direction
of associations between pathological ﬁndings. Linear
regression was used to determine relationships between
clinical features and pathological ﬁndings. Test
characteristics were calculated using receiver operating
characteristic (ROC) curves and 2×2 contingency tables.
A test was considered diagnostic when sensitivity >75%
and speciﬁcity >95% or sensitivity >95% and speciﬁcity
>75%. Intra-observer and inter-observer agreement was
calculated using Bland-Altman plots and Cohen’s κ statis-
tic (κ). Repeat counts were within 95% conﬁdence inter-
vals using Bland-Altman plots and κ was ≥0.7 indicating
good intra-observer and good or excellent inter-observer
reliability. Statistical signiﬁcance was set at p<0.05.
RESULTS
Pathological findings in Griggs pathologically definite IBM
p62, TDP-43, ubiquitin, myotilin and αB-crystallin immu-
noreactive aggregates were present in all six IBM cases
but not in normal controls (ﬁgure 1A–E). p62 and
αB-crystallin immunoreactive aggregates were present in
a greater percentage of ﬁbres than the pathological fea-
tures required in the Griggs criteria (p<0.05; ﬁgure 2).
Despite their abundance, αB-crystallin immunoreactive
aggregates were difﬁcult to quantify due to a signiﬁcant
variability in their morphology. No immunoreactive
deposits were observed in IBM cases or normal controls
with antibodies to tau and phosphorylated tau, Aβ,
α-synuclein, desmin, emerin, lamin A/C, FUS or VCP.
Alkalinised Congo red staining was more sensitive than
crystal violet and thioﬂavin S staining for observing
amyloid aggregates (ﬁgure 1F). Tissue sections contain-
ing congophilic deposits identiﬁed under ﬂuorescence
light showed no apple-green birefringence under
polarised light. Mitochondrial changes and increased
sarcolemmal and sarcoplasmic MHC class I staining
were observed in all six IBM cases, but not in normal
controls. The inﬂammatory inﬁltrate was predominantly
composed of endomysial CD8 T cells and macrophages,
with relatively few B cells.
Quantitative analysis of pathological features in IBM and
disease controls
Having shown that p62, TDP-43, ubiquitin and myotilin
aggregates, congophilic deposits, MHC class I and
inﬂammatory cells were prevalent in Griggs pathologic-
ally deﬁnite IBM, the presence of these abnormalities,
together with mitochondrial changes were assessed in
IBM+RV, IBM− RV and disease controls.
The percentage of ﬁbres containing p62, TDP-43,
myotilin and ubiquitin aggregates and congophilic
deposits were greater in IBM+RV than in IBM− RV;
there was no difference in the number of COX−/SDH+
ﬁbres (ﬁgure 3A–F). Protein aggregates were observed
in morphologically normal ﬁbres and in ﬁbres exhibit-
ing pathological features included in the Griggs criteria.
p62 and TDP-43 positive aggregates were present in a
greater percentage of ﬁbres in IBM+RV compared to
PAM; however, there were no differences in the percent-
age of ﬁbres containing myotilin and ubiquitin aggre-
gates or congophilic deposits. The percentage of ﬁbres
containing p62, TDP-43 and ubiquitin aggregates or con-
gophilic deposits were similar in IBM−RV and
PM&DM; however, myotilin aggregates were present in a
greater percentage of ﬁbres in PM&DM and COX
−/SDH+ ﬁbres were more abundant in IBM− RV.
Analysis of the total inﬂammatory inﬁltrate (the sum of
the semiquantitative scores for T cells, B cells and macro-
phages) in the endomysium, perimysium and perivascu-
lar areas revealed that there were greater numbers of
inﬂammatory cells in the endomysium and perimysium
in IBM+RV than in PAM (p<0.03). The same analysis
comparing the sum of the inﬂammatory cells in IBM−
RV and PM&DM revealed that the distribution and
intensity of the inﬂammatory inﬁltrate was similar.
Diagnostic utility of pathological features in IBM and
disease controls
To mimic the diagnostic difﬁculty encountered in clin-
ical practice, the ability of each test to differentiate
between myopathies containing rimmed vacuoles (IBM
+RV and PAM) and between inﬂammatory myopathies
(IBM − RV and PM&DM) was assessed.
Diagnostic utility determined using ROC curves
Individually, the presence of p62 immunoreactive inclu-
sions and COX−/SDH+ ﬁbres had the highest sensitivity
and speciﬁcity for differentiating IBM+RV from PAM,
(see online supplementary ﬁgure S3 and table 1).
Differentiating between IBM − RV and PM&DM, myoti-
lin positive inclusions and COX−/SDH+ ﬁbres had the
highest sensitivity and speciﬁcity (see online supplemen-
tary ﬁgure S4 and table 1). Only the presence of myoti-
lin positive inclusions satisﬁed criteria to be considered
suitable as a diagnostic test (<0.01% of ﬁbres containing
myotilin aggregates had a sensitivity of 100% and speciﬁ-
city of 82% for IBM−RV).
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Diagnostic utility determined by comparing proportion of
affected cases in each diagnostic group
In the aforementioned experiments, the number of
ﬁbres within each muscle biopsy was quantiﬁed.
However, this is impractical for routine clinical use.
Thus, the proportions of affected cases in each group
were compared (table 2). This revealed that neither
staining for protein aggregates nor congophilic deposits
could differentiate between IBM+RV and PAM. The
pathological ﬁndings in IBM− RV and PM&DM were
Figure 1 Protein aggregates
and congophilic deposits in IBM.
Stained cryostat sections,
showing fibres, often in clusters,
containing protein aggregates
stained for p62 (A), TDP-43 (B),
ubiquitin (C), αB-crystallin (D) and
myotilin (E). Protein aggregates
were present throughout fibres,
and were observed in apparently
normal fibres, vacuolated fibres
and fibres surrounded by
inflammatory infiltrates. In fibres
containing TDP-43 aggregates,
myonuclear TDP-43 staining was
frequently reduced (B).
Congophilic deposits were
observed in vacuolated fibres
using epifluorescence (F). Tissue
sections were examined using
both the rhodamine red and
fluorescein isothiocyanate filters
to exclude areas of
autofluorescence (arrow).
Combined fluorescent image is
shown. Four patterns of
immunoreactivity were observed
in IBM and disease controls
stained for p62 using IHC (G–J.
Pattern I (G)—strongly stained,
discreet and clearly delineated,
round or angular aggregates,
variable in number and size within
a muscle fibre but rarely filling it
and predominantly located
subsarcolemmal, but also
perinuclear and adjacent to
vacuoles. Pattern II (H)—large
aggregates of variable staining
intensity. Pattern III (I)—fine
granular aggregates dispersed
throughout the fibre. Pattern IV
( J)—fine granules and wisps of
p62 immunoreactivity set within
weakly basophilic inclusions.
Scale bar represents 50 µm in A
and D; 25 µm in B, C , E and F;
20 μm in G and H; 15 μm in I;
and 10 μm in J. IBM, inclusion
body myositis; IHC,
immunohistochemistry; TDP-43,
transactivation response DNA
binding protein-43.
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also similar, except that the absence of myotilin immu-
noreactive aggregates was sensitive and speciﬁc for IBM
−RV. COX−/SDH+ ﬁbres were also suggestive of IBM−
RV; one or more COX−/SDH+ ﬁbres had a sensitivity of
100% and a speciﬁcity of 73% for IBM −RV.
Increased MHC class I expression lacked speciﬁcity.
However, strong (diffuse sarcolemmal and sarcoplasmic)
MHC class I upregulation was diagnostic for IBM+RV,
differentiating it from PAM, as were the presence of
either endomysial CD3 T-cell, CD4 T-cell, or CD68
macrophage scores >1 or an endomysial CD8 T-cell
score >0. Partial invasion was speciﬁc for IBM+RV, but
lacked sensitivity. Although the sum of the inﬂammatory
inﬁltrate was similar in IBM− RV and PM&DM, analysis
of the inﬂammatory cell subtypes revealed greater
numbers of perimysial CD3 T cells, CD8 T cells and
endomysial B cells (were observed) in PM&DM than in
IBM−RV (p≤0.02), however, this was not diagnostically
useful. There was no difference in the proportion of
cases with ﬁbres undergoing partial invasion between
IBM−RV and PM&DM.
As IBM−RV is more pathologically akin to PM than
DM, analyses were repeated comparing IBM−RV and
PM cases (n=6). No p62, TDP-43 or ubiquitin immunor-
eactive aggregates were observed in PM cases and the
diagnostic utility of tests for differentiating between IBM
− RV and PM yielded similar results to prior analyses
between IBM− RV and PM&DM.
Diagnostic utility of categorising the pattern of p62 staining
The pattern of p62 staining could be categorised into
four distinct groups (ﬁgure 1G–J). Aggregates observed
in IBM were present in vacuolated and non-vacuolated
ﬁbres and were strongly stained, discreet and clearly deli-
neated, round or angular and typically located subsarco-
lemmal, perinuclear and perivacuolar (pattern I). This
pattern was observed in every IBM case with p62 aggre-
gates, one (9%) case of DM and three (43%) cases of
PAM (hereditary inclusion body myopathy, dystrophino-
pathy and genetically undeﬁned MFM). Deﬁning the
pattern of immunoreactivity increased the discriminative
value of p62 IHC for differentiating IBM+RV from PAM;
pattern I p62 aggregates compared to any p62 aggre-
gates increased the speciﬁcity from 14% to 57%, with no
loss of sensitivity. Differentiating IBM− RV and PM&DM,
pattern I p62 aggregates were highly speciﬁc (91%), but
lacked sensitivity (44%). Patterns II, III and IV were not
observed in any IBM cases. Patterns II and III appeared
to be speciﬁc for PAM (n=2; 26%), both were cases of
myotilinopathy (n=2; 67%), and DM (n=2; 40%),
respectively. Pattern IV occurred in a genetically
undeﬁned case of MFM. No differences were observed
in the morphology of TDP-43, myotilin or ubiquitin
aggregates between biopsies.
Clinicopathological correlation
In IBM+RV, IBM−RV and pathologically deﬁnite IBM,
there were no correlations in individual biopsies
between pathological features. No relationships were
identiﬁed between the pathological ﬁndings and age at
symptom onset, age at biopsy, disease duration or serum
creatine kinase. The same results were obtained when
the IBM groups were analysed separately and as one.
Proposed diagnostic algorithm
On the basis of our pathological ﬁndings, we propose a
diagnostic algorithm for differentiating IBM from its
disease mimics (ﬁgure 4).
The algorithm was tested in a further 23 cases that ful-
ﬁlled the criteria for IBM+RV (n=12) and IBM −RV
(n=11). The algorithm correctly diagnosed 20 (87%)
cases: 12 (100%) cases of IBM+RV and 8 (73%) cases of
IBM −RV. In IBM− RV, COX−/SDH+ ﬁbres were
present in 8 (73%) cases, pattern I p62 aggregates in 8
(73%) cases and both in 6 (55%) cases.
DISCUSSION
While the Griggs pathological criteria have been
accepted as diagnostic of IBM, many patients who,
observed over time undoubtedly have IBM, lack one or
more of the Griggs pathological features at presentation,
even on repeat biopsy.8 11 Despite IBM being associated
Figure 2 Box and whisker plot illustrating the percentage of
muscle fibres containing pathological abnormalities included
in the Griggs criteria and protein aggregates in Griggs
pathologically definite inclusion body myositis (IBM). Fibres
containing aggregates immunoreactive for p62 and
αB-crystallin were more frequent than those containing the
current diagnostic pathological features (red bars; p<0.05).
Protein aggregates recognised by all antibodies were found in
a significantly larger number of fibres than partial invasion
(p<0.02). TDP-43, transactivation response DNA binding
protein-43.
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with a characteristic pattern of ﬁnger ﬂexor and knee
extensor weakness, not all patients have this pattern at
disease onset, and muscle biopsy remains an important
tool in differentiating IBM from its mimics. We sought
to determine which additional pathological features
support a diagnosis of IBM, demonstrating that charac-
teristic p62 immunoreactive aggregates, strong MHC
class I upregulation, endomysial CD3 T-cell score >1,
CD8 T-cell score >0 and COX−/SDH+ ﬁbres are features
with sufﬁcient sensitivity and speciﬁcity to differentiate
IBM from pathologically similar myopathies and we
propose an easily applied pathological algorithm for the
diagnosis of IBM (ﬁgure 4).
In agreement with previous studies, we observed
p62,18 TDP-43,19 ubiquitin13 and αB-crystallin20 immu-
noreactive aggregates and a predominantly endomysial
inﬂammatory inﬁltrate3 in Griggs pathologically deﬁnite
IBM. Diagnostic pathological studies of IBM have con-
centrated on differentiating IBM from other inﬂamma-
tory myopathies and two recent quantitative studies have
found that TDP-43 and markers of autophagy such as
p62 and LC3 may be of diagnostic use.21 22 However, in
Figure 3 Box and whisker plots
illustrating the percentage of
fibres in each diagnostic category
containing p62 (A), TDP-43 (B),
myotilin (C) and ubiquitin (D)
immunoreactive aggregates,
congophilic deposits (E) and COX
−/SDH+ fibres (F). All protein
aggregates were present in a
greater percentage of fibres in
IBM+RV than in IBM - RV. There
was no difference in the
percentage of COX−/SDH+
muscle fibres between these
groups. IBM+RV biopsies had a
greater percentage of fibres
containing p62 (A) and TDP-43
(B) immunoreactive aggregates
and COX−/SDH+ fibres (F) than
PAM. Pathological findings were
similar in IBM - RV and PM&DM,
with no differences in the
percentage of fibres containing
p62 (A), TDP-43 (B) and ubiquitin
(D) immunoreactive aggregates or
congophilic deposits (E).
However, there was a greater
percentage of COX−/SDH+ fibres
(F) in IBM - RV than PM&DM and
a greater percentage of fibres
containing myotilin
immunoreactive aggregates (C) in
PM&DM than IBM - RV.
*Statistically significant results.
COX, cytochrome oxidase; IBM,
inclusion body myositis; PAM,
protein accumulation myopathies
with rimmed vacuoles; PM&DM,
steroid-responsive inflammatory
myopathies; SDH, succinate
dehydrogenase; TDP-43,
transactivation response DNA
binding protein-43.
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these studies only a fraction of each biopsy was analysed.
We have found this limited quantiﬁcation does not cor-
relate with the percentage of affected ﬁbres in a biopsy
nor does it reﬂect the way in which a muscle biopsy is
assessed. Additionally, studies have lacked protein accu-
mulation myopathies with rimmed vacuoles control
cases as it is believed that the inﬂammatory changes
present in IBM enable it to be easily differentiated from
other vacuolar myopathies.22 However, inﬂammatory
changes are frequently observed in muscular dystrophies
and the degree of inﬂammatory change necessary to
conﬁdently diagnose IBM is currently unknown.
To mimic the typical diagnostic conundrums encoun-
tered in clinical practice, we evaluated the ability of the
pathological ﬁndings to differentiate IBM+RV from
other vacuolar myopathies and IBM− RV from
steroid-responsive inﬂammatory myopathies. We found
that quantitative analysis of protein aggregates, congo-
philic deposits and COX−/SDH+ ﬁbres was of limited
diagnostic use. Analysing the biopsies dichotomously
and using a semiquantitative score-tool to assess the
inﬂammatory changes revealed that increased MHC
class I labelling was sensitive for IBM making it a good
initial screening test, its absence excluding the diagnosis.
In agreement with an earlier study, we found that p62
aggregates identiﬁed the largest number of affected
ﬁbres in IBM.23 Additionally, as a novel ﬁnding, the
morphology and distribution of p62 aggregates was char-
acteristic in IBM. This characteristic pattern of p62
immunoreactive aggregates was highly sensitive for IBM
+RV (100%); their absence from a biopsy containing
rimmed vacuoles effectively ruling-out a diagnosis of
IBM. We conﬁrmed that the most diagnostically useful
pathological ﬁndings in IBM+RV were evidence of an
immune-mediated process; strong MHC class I staining,
endomysial CD3 T-cell score >1 or an endomysial CD8
T-cell score >0 were diagnostic. Having identiﬁed any of
these features in a biopsy containing rimmed vacuoles
no extra diagnostic certainty was gained from observing
partial invasion, COX−/SDH+ ﬁbres or congophilic
deposits.
The most discriminative pathological tests for differen-
tiating between IBM− RV and PM&DM were COX/SDH
staining and myotilin IHC. Consistent with a recent
study,9 we found that the absence of mitochondrial
changes casts doubt on a diagnosis of IBM. There was
no difference in the median age between IBM−RV and
PM&DM cases to account for the difference observed in
COX−/SDH+ ﬁbres. The presence of myotilin and ubi-
quitin immunoreactive aggregates appeared to rule out
a diagnosis of IBM− RV. However, we believe that the
presence of these features in IBM+RV indicates that they
are unlikely to be diagnostically reliable features for dif-
ferentiating between IBM−RV and steroid-responsive
inﬂammatory myopathies. Although no pathological
feature was able to differentiate IBM− RV from steroid
responsive inﬂammatory myopathies with certainty the
presence of characteristic p62 aggregates and the
absence of COX−/SDH+ ﬁbres may help in supporting
and opposing a diagnosis of IBM −RV, respectively.
Pattern I p62 immunoreactive aggregates were only
present in 44% of the initial IBM−RV cases tested, but
they were not observed in PM cases and were very rare
in DM. Although pattern I p62 aggregates appear to
lack sensitivity their speciﬁcity was 91% making their
presence highly suggestive of a diagnosis of IBM− RV.
However, we identiﬁed pattern I p62 aggregates in 8 of
11 (73%) further cases of IBM− RV that were assessed
indicating that they may have a greater sensitivity and
that p62 IHC warrants further investigation and valid-
ation in a larger, independent series. The diagnostic
utility of the other patterns of p62 staining is uncertain.
Although pattern II appeared to have some speciﬁcity
for myotilinopathy the small number of cases makes
drawing any conclusion problematic. In addition to p62
other autophagic proteins have been found in IBM and
suggested as diagnostic markers.22 Autophagy is a cellu-
lar mechanism for degrading and recycling cellular
proteins and organelles. Therefore, altered autophagy
could lead to the accumulation of abnormal mitochon-
dria and misfolded aggregation-prone proteins and
may also result in altered antigen presentation leading
Table 1 Test characteristics
IBM+RV vs PAM IBM - RV vs PM&DM
Test feature AUC
Cut-off (% of
affected fibres) Sensitivity Specificity AUC
Cut-off (% of
affected fibres) Sensitivity Specificity
Rimmed vacuoles 0.60 >0.28 0.53 0.71 – – – –
p62 aggregates 0.87 >0.48 0.87 0.86 0.60 >0.21 0.22 0.91
TDP-43 aggregates 0.80 >0.34 0.80 0.86 0.53 <0.01 0.89 0.18
Ubiquitin aggregates 0.68 >0.18 0.53 0.86 0.64 <0.01 1.00 0.27
Myotilin aggregates 0.55 <2.50 1.00 0.29 0.91 <0.01 1.00 0.82
Congophilic deposits 0.56 >0.24 0.73 0.71 0.56 >0.03 0.11 1.00
COX−/SDH+ fibres 0.87 >0.04 0.86 0.86 0.93 >0.1 0.78 0.91
AUC, area under the curve; COX, cytochrome oxidase; IBM, inclusion body myositis; PAM, protein accumulation myopathies with rimmed
vacuoles; PM&DM, steroid-responsive inflammatory myopathies; RV, rimmed vacuoles; SDH, succinate dehydrogenase; TDP-43,
transactivation response DNA binding protein-43.
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Table 2 Comparison of the proportion of positive cases in each group
Pathological features
IBM+RV PAM IBM+RV vs PAM IBM - RV PM&DM IBM - RV vs PM&DM
IBM+RV vs
IBM - RV
n (%) n (%) Sensitivity Specificity n (%) n (%) Sensitivity Specificity p value
Number of cases 15 (100) 7 (100) 9 (100) 11 (100)
Aggregated proteins, n (%)
p62 15 (100) 6 (86) 1.00 0.14 4 (44) 3 (27)* 0.44 0.73 0.003†
TDP-43 13 (87) 5 (71) 0.87 0.29 1 (11) 2 (18)* 0.11 0.82 0.001†
Ubiquitin 11 (73) 4 (57) 0.73 0.43 0 (0) 3 (27)* 0.00 0.73 0.001†
Myotilin 10 (67) 5 (71) 0.67 0.29 0 (0) 9 (82) 0.00 0.18 0.002†
Congophilic deposits 13 (87) 7 (100) 0.87 0.00 1 (11) 0 (0) 0.11 1.00 0.001†
COX−/SDH+ fibres‡, n (%)
Any 12 (86) 2 (29) 0.86 0.71 9 (100) 3 (27) 1.00 0.73 0.50
Inflammatory features, n (%)
MHC class I upregulation 15 (100) 3 (43) 1.00 0.57 7 (78) 11 (100) 0.78 0.00 0.13
Strong MHC class I upregulation 14 (93) 0 (0) 0.93 1.00 9 (100) 10 (91) 1.00 0.09 1.00
Partial invasion 10 (67) 0 (0) 0.67 1.00 3 (33) 2 (18) 0.33 0.82 0.21
Endomysial CD3 T-cell score >1 13 (87) 0 (0) 0.87 1.00 4 (44) 7 (64) 0.44 0.36 0.06
Endomysial CD4 T-cell score >1 12 (80) 0 (0) 0.80 1.00 2 (22) 5 (45) 0.22 0.54 0.01†
Endomysial CD8 T-cell score >0 14 (93) 0 (0) 0.93 1.00 7 (78) 9 (82) 0.78 0.18 0.53
Endomysial CD68 macrophage score >1 12 (80) 0 (0) 0.80 1.00 4 (44) 8 (73) 0.44 0.27 0.10
*Pathological features present in DM, but not PM cases.
†Statistically significant results.
‡In IBM with rimmed vacuoles n=14.
COX, cytochrome oxidase; IBM, inclusion body myositis; MHC, major histocompatibility complex; PAM, protein accumulation myopathies with rimmed vacuoles; PM&DM, steroid-responsive
inflammatory myopathies; RV, rimmed vacuoles; SDH, succinate dehydrogenase; TDP-43, transactivation response DNA binding protein-43.
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to the widespread increase of MHC class I. The pres-
ence of mitochondrial changes, aggregated proteins
and MHC class I upregulation in IBM suggests that
altered autophagy may play an important role in the
pathogenesis.
A number of pathological features—protein aggre-
gates, congophilic deposits and some inﬂammatory
changes—were more abundant in IBM+RV than IBM−
RV. Despite using slightly different inclusion criteria,
similar differences have been reported between patho-
logically typical and pathologically atypical IBM.21
However, we found no differences in the number of
COX−/SDH+ ﬁbres, the degree of MHC class I upregu-
lation, the morphology and distribution of p62 immu-
noreactive aggregates or the pattern of the
inﬂammation between IBM+RV and IBM− RV, support-
ing our clinical observations that these are the same
disease. We believe that the pathological differences
between IBM+RV and IBM− RV are, in part, due to
differences in disease duration. Two studies have shown
that rimmed vacuoles are more common in patients who
are older at the time of muscle biopsy,11 24 suggesting
that they are associated with chronologically more
advanced disease. Therefore, the pathological ﬁndings
which are more abundant in IBM+RV and thought to be
typical of IBM may instead be indicative of chronologic-
ally more advanced disease explaining their limited sen-
sitivity at disease presentation. However, possibly due to
the number of cases analysed, we were unable to
conﬁrm a relationship between pathological features
and clinical ﬁndings. It could be argued that biopsies
from different muscles may have affected the patho-
logical ﬁndings observed and differences between IBM
groups. However, in a recent review of 59 muscle biop-
sies from IBM cases in our clinical archive with quadri-
ceps (n=31) and deltoid (n=28) biopsies we found no
signiﬁcant difference in the frequency of pathological
ﬁndings.
Figure 4 Proposed diagnostic algorithm for IBM based on pathological findings. Increased MHC class I staining was observed
in all cases of IBM and pattern I p62 aggregates in all cases of IBM+RV making them good initial screening tests. Their absence
rules out a diagnosis of IBM and IBM+RV, respectively. The presence of endomysial CD3 T-cell score >1, endomysial CD8 T-cell
score >0 or strong MHC class I staining in a biopsy with rimmed vacuoles and pattern I p62 aggregates secures a diagnosis of
IBM+RV. Differentiating IBM - RV and PM&DM pathologically is more challenging. The presence of COX−/SDH+ fibres is not
specific to IBM - RV; although COX−/SDH+ fibres were not present in every case of IBM - RV their absence casts doubt on the
diagnosis of IBM - RV. Pattern I p62 aggregates may enable IBM - RV to be differentiated from PM when present. However, they
may lack sensitivity for IBM - RV and therefore, their absence does not rule out the diagnosis. COX, cytochrome oxidase; GT,
Gomori trichrome; IBM, inclusion body myositis; MHC, major histocompatibility complex; PM&DM, steroid-responsive
inflammatory myopathies; SDH, succinate dehydrogenase.
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A robust clinicopathological deﬁnition of IBM is of
paramount importance for diagnosis and for selection
and entry of patients into clinical trials. We have shown
that certain pathological ﬁndings are more abundant
than those included in the current pathologically
focused diagnostic criteria. Moreover, p62 immunoreac-
tive deposits, increased MHC class I expression, endomy-
sial CD3 T cells and CD8 T cells and COX−/SDH+
ﬁbres have sufﬁcient sensitivity and speciﬁcity to aid in
the histological differentiation of IBM from disease
mimics, supporting their inclusion in future diagnostic
criteria for IBM alongside clinical criteria. Both CD3 T
cells and CD8 T cells are included in the diagnostic algo-
rithm as there was little difference in their sensitivity and
speciﬁcity for differentiating IBM+RV from PAM.
However, IHC staining for CD3 T cells is likely to be
more widely available and avoids the costs of extra stain-
ing to subtype the inﬂammatory inﬁltrate enabling the
diagnostic algorithm to be used by a greater number
diagnostic laboratories. Using our diagnostic algorithm,
we found that there would be little additional diagnostic
security in identifying partial invasion, performing EM
or staining for amyloid deposits. Finally, mitochondrial
changes and MHC class I upregulation were the most
consistent ﬁndings in our IBM cases suggesting that they
are central to the pathogenesis and that further investi-
gation and therapeutic intervention should be directed
towards these features.
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Correction
Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying the principal patho-
logical features useful in the diagnosis of inclusion body myositis. BMJ Open 2014;4:e004552.
During the production process some errors to the values in table 2 were inadvertently intro-
duced, speciﬁcally to the values in the rows entitled ‘MHC class I upregulation’ and ‘Strong
MHC class I upregulation’, and columns ‘IBM - RV n (%)’, ‘IBM - RV vs PM&DM Sensitivity’
and ‘IBM+RV vs IBM - RV p value.’ The correct table is provided below.
BMJ Open 2014;4:e004552corr1. doi:10.1136/bmjopen-2013-004552corr1
BMJ Open 2014;4:e004552corr1. doi:10.1136/bmjopen-2013-004552corr1 1
Miscellaneous
Table 2 Comparison of the proportion of positive cases in each group
Pathological features
IBM+RV PAM IBM+RV vs PAM IBM - RV PM&DM IBM - RV vs PM&DM
IBM+RV vs
IBM - RV
n (%) n (%) Sensitivity Specificity n (%) n (%) Sensitivity Specificity p value
Number of cases 15 (100) 7 (100) 9 (100) 11 (100)
Aggregated proteins, n (%)
p62 15 (100) 6 (86) 1.00 0.14 4 (44) 3 (27)* 0.44 0.73 0.003†
TDP-43 13 (87) 5 (71) 0.87 0.29 1 (11) 2 (18)* 0.11 0.82 0.001†
Ubiquitin 11 (73) 4 (57) 0.73 0.43 0 (0) 3 (27)* 0.00 0.73 0.001†
Myotilin 10 (67) 5 (71) 0.67 0.29 0 (0) 9 (82) 0.00 0.18 0.002†
Congophilic deposits 13 (87) 7 (100) 0.87 0.00 1 (11) 0 (0) 0.11 1.00 0.001†
COX−/SDH+ fibres‡, n (%)
Any 12 (86) 2 (29) 0.86 0.71 9 (100) 3 (27) 1.00 0.73 0.50
Inflammatory features, n (%)
MHC class I upregulation 15 (100) 3 (43) 1.00 0.57 9 (100) 11 (100) 1.00 0.00 1.00
Strong MHC class I upregulation 14 (93) 0 (0) 0.93 1.00 7 (78) 10 (91) 0.78 0.09 0.53
Partial invasion 10 (67) 0 (0) 0.67 1.00 3 (33) 2 (18) 0.33 0.82 0.21
Endomysial CD3 T-cell score >1 13 (87) 0 (0) 0.87 1.00 4 (44) 7 (64) 0.44 0.36 0.06
Endomysial CD4 T-cell score >1 12 (80) 0 (0) 0.80 1.00 2 (22) 5 (45) 0.22 0.54 0.01†
Endomysial CD8 T-cell score >0 14 (93) 0 (0) 0.93 1.00 7 (78) 9 (82) 0.78 0.18 0.53
Endomysial CD68 macrophage score >1 12 (80) 0 (0) 0.80 1.00 4 (44) 8 (73) 0.44 0.27 0.10
*Pathological features present in DM, but not PM cases.
†Statistically significant results.
‡In IBM with rimmed vacuoles n=14.
COX, cytochrome oxidase; IBM, inclusion body myositis; MHC, major histocompatibility complex; PAM, protein accumulation myopathies with rimmed vacuoles; PM&DM, steroid-responsive
inflammatory myopathies; RV, rimmed vacuoles; SDH, succinate dehydrogenase; TDP-43, transactivation response DNA binding protein-43.
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